CCO Infectious Disease Podcast

Key Decisions in HIV Care: Treatment Considerations for Transgender PWH

Episode Summary

Listen as Dr Michelle D. Collins-Ogle shares some of the key considerations for ART management for transgender PWH, including providing care within a gender-affirmative care model, considering drug–drug interactions between hormone therapy and ART, and addressing barriers to engagement and retention in care.

Episode Notes

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for transgender people with HIV (PWH).

Listen as she gives perspectives on:

• Department of Health and Human Services (DHHS) guideline recommendations for transgender PWH
• Providing HIV care within a gender-affirmative care model, including discussion of strategies, barriers, and facilitators
• Gender-affirmative hormone therapy options
• Drug–drug interaction potential between gender-affirmative hormone therapy and antiretroviral therapy
• Recommended laboratory monitoring while receiving gender-affirming hormone therapy
• The cascade of care for transgender PWH and barriers to engagement and retention in care

Presenter:

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV  
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein  
College of Medicine
Bronx, New York  

Follow along with the slides at:
https://bit.ly/3wOdKVo

Link to full program:
https://bit.ly/3fOl0XX